Dextromethorphan Hbr, Guaifenesin

—

In supply · Australia

Pecgen Dmx

In supply · 🇦🇺 Australia · short in🇺🇸 US

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Therapeutic category
Active ingredient (INN)	Dextromethorphan Hbr, Guaifenesin
Brand names	Pecgen Dmx

Controlled substance	No

Marketing-authorisation holders	OPMX LLC

Registrations on file	1

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Recalls official enforcement reports

🇺🇸

ROMPE PECHO

Efficient Laboratories, Inc. · Aug 2021

Class IIdetails ↗

🇺🇸

CHILDRENS ROBITUSSIN HONEY COUGH AND CHEST CONGESTION DM

Glaxosmithkline Consumer Healthcare Holdings · June 2020

Class IIdetails ↗

🇺🇸

PECGEN DMX

Novis PR, Inc. · May 2019

Class Idetails ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders1 registration · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
DEXTROMETHORPHAN HBR, GUAIFENESIN	20; 400mg/1; mg/1	capsule	🇺🇸 US	OPMX LLC	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.